Argenx SE – ADR (ARGX) Sentiments Bolstered on Vyvgart FDA Priority Review Milestone

Argenx SE – ADR (NASDAQ:ARGX) is one of the best healthcare stocks to buy for 2026. On January 13, Argenx SE – ADR (NASDAQ: ARGX) saw its market sentiment boosted after the US Food and Drug Administration accepted priority review for a supplemental biologics license application for the immune disorder drug Vyvgart.

Argenx SE – ADR (ARGX) Sentiments Bolstered on Vyvgart FDA Priority Review Milestone

The company submitted the application to expand the use of candidate drugs for treating adults with acetylcholine receptor antibody-seronegative generalized myasthenia gravis (gMG). If successful, the license would broaden the patient population eligible for the medication. The FDA has already granted priority review status, which is expected to accelerate regulatory decision timelines for the expanded drug indication.

Earlier, on January 12, William Blair reiterated an Outperform rating on the stock, impressed by the company’s strong sales momentum in its Vyvgart franchise. Sales for the candidate drug continue to exceed expectations, with the momentum expected to continue throughout 2026 and across indications in MG (myasthenia gravis) and CIDP (chronic inflammatory demyelinating polyneuropathy)

The research firm is also confident in the company’s other clinical assets, including empasiprubart for MMN (multifocal motor neuropathy), which presents a blockbuster opportunity.

Argenx SE – ADR (NASDAQ:ARGX) is a Netherlands-based global biotechnology company focused on developing, manufacturing, and commercializing antibody-based therapies for severe autoimmune diseases and cancers.

While we acknowledge the potential of Argenx SE – ADR (NASDAQ:ARGX) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ARGX and that has 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: 12 Best Consumer Goods Stocks Billionaires Are Quietly Buying and Goldman Sachs Penny Stocks: Top 12 Stock Picks.

Disclosure: None. This article is originally published at Insider Monkey.